Welcome to our dedicated page for Carecloud SEC filings (Ticker: CCLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CareCloud, Inc. (CCLD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed healthcare technology company with common stock (CCLD) and 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (CCLDO), CareCloud uses SEC filings to report material events, financial results, acquisitions, and capital structure updates.
Investors can review current reports on Form 8-K that describe significant developments such as quarterly earnings releases, preferred stock dividend declarations, acquisitions, and governance matters. For example, recent 8-K filings have covered the announcement of preferred stock dividend payments, the acquisition of Medsphere Systems Corporation and related financial statements, the acquisition of HFMA’s MAP App, and notices regarding Nasdaq listing rule compliance following changes in board composition.
Filings also document financial performance and guidance. Earnings-related 8-Ks incorporate press releases that discuss revenue, profitability, adjusted EBITDA, and management’s expectations, while accompanying exhibits may include presentation slides and non-GAAP reconciliations. These materials help investors understand how CareCloud’s AI-driven and technology-enabled solutions, acquisitions, and operational initiatives affect its financial results.
CareCloud’s SEC disclosures further address preferred stock terms and dividends, including details on its 8.75% Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. Filings and exhibits describe dividend rates, payment schedules, redemption provisions, and, in the case of Series A, events such as mandatory conversion and delisting from Nasdaq when that series no longer met continued listing requirements.
On Stock Titan, AI-powered tools can summarize lengthy filings and highlight key points, such as changes in revenue guidance, acquisition impacts, or updates on preferred dividend plans. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks as they become available from EDGAR, while also tracking any Form 4 insider transaction reports that may be filed. This page is designed to help readers interpret CareCloud’s regulatory history and stay informed about how corporate actions, acquisitions, AI initiatives, and capital decisions are reflected in its official SEC record.
CareCloud director Lawrence S. Sharnak reported an equity award vesting and share issuance. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of CareCloud common stock at a price of $0. According to the filing, these restricted stock units and the resulting shares were granted under the company’s Amended and Restated Equity Incentive Plan without payment by Sharnak.
Following the transaction, Sharnak directly owned 127,750 shares of common stock and 26,250 restricted stock units. This reflects routine compensation-related activity rather than an open-market purchase or sale.
CareCloud, Inc. director Cameron Munter reported a routine equity compensation vesting. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a price of $0 per share, under the company’s Amended and Restated Equity Incentive Plan.
After this conversion, Munter directly beneficially owned 202,750 shares of CareCloud common stock and 26,250 restricted stock units. The transaction involved no cash payment by the reporting person and reflects standard compensation-based vesting rather than an open‑market purchase or sale.
CareCloud, Inc. director Anne Busquet reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by her.
After this equity award vesting, she directly holds 295,138 shares of CareCloud common stock and 26,250 derivative securities in the form of restricted stock units.
CareCloud, Inc. director Bill Korn reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by Korn.
After this transaction, Korn beneficially owns 211,633 shares of CareCloud common stock directly and 26,250 restricted stock units, reflecting his ongoing equity-based compensation as a director.
CareCloud, Inc. director Bill Korn reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Korn. Following this transaction, he directly owned 204,133 shares of common stock and 33,750 restricted stock units.
CareCloud, Inc. director Anne Busquet reported a routine equity award vesting and conversion. On January 31, 2026, 6,250 restricted stock units vested and converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Busquet.
After this transaction, she directly holds 287,638 shares of common stock and 33,750 restricted stock units, reflecting ongoing participation in CareCloud’s long‑term incentive program rather than an open‑market purchase or sale.
CareCloud director Lawrence Steven Sharnak reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of CareCloud common stock at a price of
After this transaction, Sharnak directly owned 120,250 shares of common stock and 33,750 restricted stock units. The award vested without cash payment by the reporting person, reflecting compensation delivered in company equity rather than cash.
CareCloud, Inc. director Cameron Munter reported the vesting and conversion of restricted stock units into common stock. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under CareCloud’s Amended and Restated Equity Incentive Plan, without payment by Munter.
After this transaction, Munter directly owned 195,250 shares of CareCloud common stock and 33,750 restricted stock units. The filing reflects equity-based compensation vesting rather than an open‑market purchase or sale.
CareCloud, Inc. furnished an update stating that its Board of Directors has declared monthly cash dividends on its Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. These dividends are scheduled for payment in February, March and April 2026, providing continued cash distributions to holders of these preferred shares during that period. Further details, including the specific dividend terms, are contained in a press release dated January 20, 2026 that is incorporated by reference as an exhibit.
CareCloud, Inc. (CCLD) reported the death of independent director John N. Daly on November 24, 2025. Mr. Daly had served on the Board since July 2014 and was a member of the Audit Committee and chairman of the Compensation Committee.
Because of his passing, the Board no longer has a majority of independent directors and the Audit Committee no longer has at least three members, causing noncompliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A). On November 25, 2025, Nasdaq granted a cure period that runs until the earlier of CareCloud’s next annual shareholder meeting or November 24, 2026. The company has informed Nasdaq that the Board plans to appoint an additional independent director to restore compliance.
FAQ
What is the current stock price of Carecloud (CCLD)?
What is the market cap of Carecloud (CCLD)?
